⸺ApiFix – an alternative to spinal fusion⸺
A treatment option for adolescent idiopathic scoliosis
ApiFix® was developed to help patients with adolescent idiopathic scoliosis (AIS) and their families make informed decisions about treatment options together with their orthopedic surgeon.

⸻ APIFIX
Bridging a treatment gap
Brace treatment is not always sufficient. For selected patients with adolescent idiopathic scoliosis (AIS), the ApiFix® procedure is a less invasive treatment option than spinal fusion. The procedure corrects spinal curvature while preserving spinal mobility and avoids the permanence of spinal fusion.
ApiFix: a simpler approach, faster recovery
The ApiFix system is implanted on only one side of the spine through a posterior approach. This makes the procedure less invasive than spinal fusion and other fusion-less techniques, which generally require a more complex anterior approach. Patients may therefore recover more quickly; they are usually discharged from the hospital after two to four days and return to school within two weeks of the ApiFix procedure.

The Internal Brace option™
At the heart of the ApiFix system is a rod that is self-adjusting in length that acts as an internal brace to straighten the spine. The rod design incorporates two polyaxial joints, which provide a greater range of motion than spinal fusion.
Predictable correction with ApiFix®
Most of the straightening of the spine is achieved during the initial procedure. After surgery, the rod is self-adjusting in length, providing additional correction while accommodating continued growth. This makes the system suitable for adolescents who have not yet finished growing.

A long-term track record of clinical success
The safety and probable benefit of the ApiFix procedure have been demonstrated in more than 800 procedures*) and over 10 years of clinical experience. Over this period, both the procedure and the system have been refined, resulting in steadily improving outcomes for patients with progressive adolescent idiopathic scoliosis.
A clinical study for FDA approval has been ongoing in the United States since 2021. The results published to date are consistent with the clinical outcomes observed over the past ten years at Sana Dreifaltigkeits Hospital Cologne.
*) Data: international (total) , as of 2023.
Source: ApiFix Ltd. is a wholly owned subsidiary of OrthoPediatrics Corp. www.orthopediatrics.com
